메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

QuidelOrtho Enters Strategic Supply Agreement to Expand Global Immunoassay Portfolio

Agreement adds new analyzer platforms and expands assay menu across key international markets SAN DIEGO, Feb. 16, 2026 -- QuidelOrtho has entered a long-term strategic supply agreement with Lifotronic Technology Co., Ltd. (Lifotronic Technology Co., Ltd., stock code: 688389), to expand QuidelOrtho's global immunoassay portfolio and accelerate customer access to scalable, high quality, cost-efficient solutions across select markets outside the United States. The agreement provides QuidelOrtho access to multiple high-throughput and low-to-mid volume immunoassay ana
- 김갑성 기자
- 2026-02-16 14:00
퀴델오쏘, 글로벌 면역분석 포트폴리오 확대 위한 전략적 공급 계약 체결

신규 분석기 플랫폼 도입 및 주요 해외 시장에서 분석 메뉴 확장 샌디에이고, 2026년 2월 16일 -- 퀴델오쏘(QuidelOrtho)가 글로벌 면역분석 포트폴리오 확대 및 미국 외 선별 시장에서 확장 가능한 고품질의 비용 효율적인 솔루션에 대한 고객 접근성을 가속하기 위해 리포트로닉 테크놀로지(Lifotronic Technology Co., Ltd., 리포트로닉 테크놀로지)(주식 코드: 688389)와 장기 전략적 공급 계약을 체결했다. 이번 계약을 통해 퀴델오쏘는 다수의 고처리량 및 저·중처리량 면역분석 분석기 플랫폼에 대한 접근 권한을 확보하게 되며, 각 플랫폼은 일반 검사 및 특수 검사를 아우르는 광범위한 분석 메뉴를 지원한다. 이번 협력을 통해 퀴델오쏘의 면역분석 메뉴는 기존 VITROS 시스템에서 제공되지 않던 25종 이상의 신규 분석이 추가될 예정이며, 새로운 파트너 플랫폼 전체에서는 총 70종 이상의 분석 메뉴가 제공될 계획이다. 이러한 포트폴리오 추가는 전체 메뉴 입찰(full-menu tenders)에 대한 경쟁력을 강화하고, 소규모 처리 솔루션을 찾는 소형
- 김갑성 기자
- 2026-02-16 14:00
Community Med Care's "Love & Share" CNY Blessing Campaign Gives the Gift of TCM Healing and Brings Hope to Children in Need

HONG KONG, Feb. 16, 2026 -- This Lunar New Year, Community Med Care is turning seasonal blessings into lasting impact. The charity's "Love & Share" CNY Blessing Campaign invites the public to support its flagship program, "Stand Up with Love: Angel Mission", which provides free Traditional Chinese Medicine (TCM) consultations to children with autism, ADHD, congenital or acquired brain damage, and other special needs, offering them not just treatment, but a chance to thrive. Acupuncture and TCM: A Path Forward for Nearly 1,300 Children The
- 김갑성 기자
- 2026-02-16 09:00
CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial

[ 메디채널 김갑성 기자 ] CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical trial in patients with advanced solid tumors. This marks a significant milestone in the global development of this innovative immunotherapy. The ongoing global multicenter Phase II trial is currently enrolling patients in Australia and China. The study design includes 15 cohorts evaluating both monotherapy and combination therapy regimens across 9 solid tumor indications, including but not limit
- 김갑성 기자
- 2026-02-16 08:10
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Colorectal Cancer of Biparatopic HER2-targeting ADC JSKN003

SUZHOU, China, Feb. 14, 2026 -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-005) of the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, for the treatment of HER2-positive advanced colorectal cancer (CRC). JSKN003 is independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK). Colorectal cancer is among the most common malignancies worldwide. Chi
- 김갑성 기자
- 2026-02-14 20:58
Visa-Free Policies Fuel New Trend in Medical Tourism: International Patients Praise Parkway in Shanghai

SHANGHAI, Feb. 14, 2026 -- With the implementation of 144-hour visa-free transit across multiple cities in China, international visitors now enjoy significantly greater convenience. Recently, an intriguing trend has emerged: many foreign nationals arriving in Shanghai for business or tourism are now incorporating "health management" or "convenient medical access" into their packed itineraries, blurring the lines between "leisure travel to China" and "medical travel in China". Parkway MediCentre Xintiandi, located in the heart of downtown Shanghai, and P
- 김갑성 기자
- 2026-02-14 20:12
SingHealth Opens Community MRI Centre at Dunearn Village in Collaboration with United Imaging

SINGAPORE, Feb. 14, 2026 -- SingHealth, Singapore's largest public healthcare cluster, has opened a new MRI centre at Dunearn Village, marking its first MRI facility located outside a hospital campus and extending diagnostic imaging services into the community. Developed in collaboration with United Imaging Healthcare, a global provider of AI-powered medical imaging equipment and healthcare solutions, the centre introduces a new operational model designed to increase imaging capacity while improving patient experience and workflow efficiency. Fully licensed and operated by RADSC
- 김갑성 기자
- 2026-02-14 20:00
HanchorBio Receives FDA Orphan Drug Designation for HCB101 in Gastric Cancer

[ 메디채널 김갑성 기자 ] First SIRPα-IgG4 Fc Fusion Protein Granted Orphan Status in Gastric Cancer TAIPEI, SHANGHAI and SAN FRANCISCO, Feb. 13, 2026 -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to HCB101 for the treatment of gastric cancer. The designation covers gastric cancer broadly, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative subtypes.
- 김갑성 기자
- 2026-02-13 14:04
Omics Empower Hong Kong Launches Xenium™ In Situ Spatial Transcriptomics Services

HONG KONG, Feb. 13, 2026 -- Omics Empower, a global life science service provider specializing in single-cell sequencing and spatial transcriptomics, announced that Xenium™ In Situ Spatial Transcriptomics services are now available at its Hong Kong Science Park laboratory. Since the launch of the Hong Kong laboratory in July 2025, Omics Empower has supported research teams with local single-cell sequencing and spatial transcriptomics services. Faster processing helps preserve RNA integrity and cell viability, supporting high-quality single-cell data generation. Xenium™, develope
- 김갑성 기자
- 2026-02-13 14:00
Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia

[ 메디채널 김갑성 기자 ] - Comprehensive review of recent milestones highlights statistically significant efficacy in prostate cancer prevention, discovery of novel lipid-modulating properties, and the execution of high-value commercial partnerships in South Korea and Vietnam. NEW TAIPEI CITY, Feb. 13, 2026 -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today issued a strategic corporate update. This review encapsulat
- 김갑성 기자
- 2026-02-13 08:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2026-03-02_MON

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 03월 02일 23시 00분